EUVIMEDEUVIMED entdecken
Crossref

Chronic Myeloid Leukemia: Where Do We Go Now?

Jorge E Cortés

Clinical Lymphoma and Myeloma · 2009-12 · 9 · S374-S375

DOI: 10.3816/clm.2009.s.036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma and Myeloma, 2009-12. Verfasst von Jorge E Cortés. Beteiligte Einrichtung: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, USA. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBenzamidesHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositivePiperazinesProtein Kinase InhibitorsPyrimidinesRemission InductionSurvival Rate

Substanzen

Antineoplastic AgentsBenzamidesPiperazinesProtein Kinase InhibitorsPyrimidinesImatinib Mesylate

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, USA.

Zitieren

APA

Cortés, J. E. (2009). Chronic Myeloid Leukemia: Where Do We Go Now?. Clinical Lymphoma and Myeloma, 9, S374-S375. https://doi.org/10.3816/clm.2009.s.036

Vancouver

Cortés JE. Chronic Myeloid Leukemia: Where Do We Go Now?. Clinical Lymphoma and Myeloma. 2009;9:S374-S375. doi:10.3816/clm.2009.s.036

BibTeX
@article{Corts2009,
  author = {Cortés, Jorge E},
  title = {Chronic Myeloid Leukemia: Where Do We Go Now?},
  journal = {Clinical Lymphoma and Myeloma},
  year = {2009},
  volume = {9},
  pages = {S374--S375},
  doi = {10.3816/clm.2009.s.036}
}
Kostenlos starten →